About
FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc.-TVI and OrbiMed Israel Partners together with the Israeli Innovation Authority of the Ministry of Economy and later joined by Leaps by Bayer, the impact investments unit of Bayer AG.
The FutuRx incubator is dedicated to the inception of early-stage biopharma ventures based on cutting edge science and supporting them in successful drug development
FutuRx strives to be a catalyst for drug development by bridging the gap between concept and proof of concept through its dedicated system and structure. FutuRx's management, together with its founders, will establish and fully support companies via its in-house laboratory and management facility.
FutuRx provides a unique model for supporting early-stage innovation, by combining expertise of FutuRx management team, and global capabilities of the founders, teamed with the Technological Incubators Program at the Israeli Innovation Authority.
Companies established by FutuRx benefit from professional assistance by industry leading experts. These global capabilities facilitate the development of innovative technologies, on the way to safely turning them into cutting-edge products for the benefit of patients and healthcare providers.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is FutuRx's primary focus as an investor?
- FutuRx operates as an incubator dedicated to the inception and support of early-stage biopharma ventures focused on cutting-edge science and drug development.
- Who are the founding partners of FutuRx?
- FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company (through Takeda Ventures Inc.-TVI), and OrbiMed Israel Partners, in collaboration with the Israeli Innovation Authority. Leaps by Bayer later joined as an investor.
- When was FutuRx established?
- FutuRx was founded in 2014.
- What is FutuRx's geographic focus for investments?
- FutuRx is based in Ness Ziona, Israel, and focuses on the Israeli market.
- Can you name some notable companies in FutuRx's portfolio?
- Notable companies in FutuRx's portfolio include BiomX, which raised $146.5M, and ImmPACT Bio, which raised $137M. For a full list, refer to startupim data.
- Has FutuRx had any exits from its portfolio companies?
- Yes, FutuRx has had two exits. BiomX underwent a Reverse Merger Event in November 2019, and ImmPACT Bio was acquired by Lyell Immunopharma in October 2024.
- What is the typical investment stage for FutuRx?
- FutuRx primarily invests in Seed and Pre-Seed stage companies, with some undisclosed stage investments.
- What is the sector concentration of FutuRx's investments?
- FutuRx's investments are exclusively concentrated in the Health Tech & Life Sciences sector, specifically in biopharmaceutical and therapeutics companies.
- What is the most recent investment made by FutuRx?
- According to startupim data, FutuRx's most recent investment was in Symbol Therapeutics in September 2022, with an amount of $3,000,000.